Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.
暴露前免疫健康及其与 SARS-COV2 血清学反应、内皮细胞弹性和心血管并发症的联系:定义高风险内型的机制基础。
基本信息
- 批准号:10855043
- 负责人:
- 金额:$ 80.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-30 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVACE2AccelerationAccidentsAcuteAdhesionsAffectAngiotensin IIAntibody ResponseAntigen ReceptorsB-Cell ActivationBlood TestsCOVID-19COVID-19 impactCOVID-19 mortalityCOVID-19 pneumoniaCOVID-19 riskCOVID-19 severityCOVID-19 survivorsCardiacCardiac MyocytesCardiopulmonaryCardiovascular DiseasesCardiovascular systemCathepsinsCause of DeathCellsCessation of lifeChronicClinicClinicalDataDiseaseDistantDown-RegulationEconomicsEndothelial CellsEndotheliumEnrollmentFailureFibrosisFoundationsFunctional disorderFutureGene ExpressionGene Expression ProfileGene Expression ProfilingGenetic TranscriptionGlucoseGoalsHealth PersonnelHeartHeart DiseasesHeart failureHeterogeneityHumanImmuneImmune System DiseasesImmunologicsImpairmentIn VitroIndividualInfectionInfection preventionInflammationInflammatoryIntegration Host FactorsInterleukin-6InterventionKnowledgeLeft Ventricular DysfunctionLifeLinkLipoproteinsLongitudinal cohortLymphopeniaMagnetic ResonanceMaintenanceMalignant NeoplasmsMeasuresModelingMolecularMolecular ProfilingMorbidity - disease rateNatureNodalOrganOutcomePathway interactionsPatientsPermeabilityPhenotypePilot ProjectsPlasmaPublishingRecoveryResearchRiskRisk FactorsSARS-CoV-2 exposureSARS-CoV-2 infectionSARS-CoV-2 pathogenesisScanningSerologySeveritiesShapesStimulusSurvivorsSymptomsT-LymphocyteT-Lymphocyte SubsetsTNF geneTechniquesTestingTissuesToxic effectVascular Endothelial CellVentricular DysfunctionViralViral PneumoniaVirusWorkadverse outcomecardiometabolismcardiovascular disorder riskcellular resiliencecohortcoronavirus diseasecytokinecytokine release syndromecytotoxicexperimental studygain of functionhigh riskimmune activationimmune functionimmune healthimmune system functionimprovedinternational centermonocytemortalitymultidisciplinaryneutralizing antibodypermissivenesspopulation healthpreventprospectiverecruitresponsesevere COVID-19single cell sequencingthrombotictranscription factortranscriptomics
项目摘要
Abstract
The objective of this proposal is to understand the immunologic foundations of heart disease which can occur
as a result of COVID19. Cardiac impairment, when it develops is often fatal, and our hypothesis is that the
maintenance of endothelial function is critical to surviving the protracted nature of COVID19 pneumonia,
especially in those with reduced or delayed antibody responses.
Our first aim will be to analyze those differences in immune function which pre-date infection but appear
to impact the risk of fatal COVID. This will be done by enrolling those at high risk for developing COVID19
(frontline healthcare workers), and performing serially assessments of their immunologic function if they develop
COVID. We will specifically investigate the mechanisms that link pre-infection inflammatory pathways to
protective serologic responses and symptom severity and recovery.
Our second aim will be to perform in vitro experiments to assess the requirements for endothelial cell
dysfunction and infectivity. We will compare various inflammatory and cardiovascular stimuli which seem to play
a role in promoting COVID19-related cardiovascular complications.
Our third aim is to characterize immune cells, endothelial cells, and cardiomyocytes in heart tissue from
those with COVID19-induced left ventricular dysfunction. Using single cell sequencing techniques, we will
determine cellular and molecular signatures that characterize the microenvironment of the COVID19-affected
heart, compared to appropriate controls.
Our conceptual model is that pre-existing immune dysfunction 1) reduces the efficiency of neutralizing
antibody responses, and 2) in conjunction with cardiovascular disease risk factors, induces endothelial
downregulation/depletion of nodal regulators which protect against inflammatory insults. This renders
endothelial cells unable to withstand COVID-specific stimuli. Once completed, this study will provide the
necessary information to improve the identification of those at risk for COVID-related heart disease and develop
rationale approaches to improve the improve survival in the setting of COVID.
摘要
本提案的目的是了解可能发生的心脏病的免疫学基础
因为COVID 19。心脏受损,当它发展时通常是致命的,我们的假设是,
维持内皮功能对于在COVID 19肺炎的长期性质中存活至关重要,
特别是在那些抗体应答降低或延迟的患者中。
我们的第一个目标将是分析那些在感染前出现的免疫功能差异,
来影响致命的COVID的风险。这将通过招募那些患有COVID 19的高风险人群来实现
(前线医护人员),并进行连续评估他们的免疫功能,如果他们发展
COVID.我们将专门研究感染前炎症通路与
保护性血清学应答和症状严重程度及恢复。
我们的第二个目标是进行体外实验,以评估内皮细胞的需求,
功能障碍和传染性。我们将比较各种炎症和心血管刺激,
在促进COVID 19相关心血管并发症中的作用。
我们的第三个目标是表征心脏组织中的免疫细胞、内皮细胞和心肌细胞,
患有COVID 19引起的左心室功能障碍的患者。使用单细胞测序技术,我们将
确定表征受COVID 19影响的微环境的细胞和分子特征
与适当的对照相比。
我们的概念模型是,预先存在的免疫功能障碍1)降低了中和的效率
抗体反应,2)与心血管疾病危险因素结合,诱导内皮细胞
下调/耗尽保护免受炎性损伤的淋巴结调节因子。这使得
内皮细胞无法承受COVID特异性刺激。一旦完成,这项研究将提供
必要的信息,以改善对那些处于COVID相关心脏病风险的识别,并制定
合理的方法来改善在COVID环境下的生存。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection.
- DOI:10.1016/j.trsl.2021.11.005
- 发表时间:2022-03
- 期刊:
- 影响因子:0
- 作者:Al-Kindi S;Zidar DA
- 通讯作者:Zidar DA
Crude lymphocyte levels: Can the past accelerate the future in preventive medicine?
粗淋巴细胞水平:过去能否加速预防医学的未来?
- DOI:10.1002/ajh.27125
- 发表时间:2023
- 期刊:
- 影响因子:12.8
- 作者:Zidar,DavidA
- 通讯作者:Zidar,DavidA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Timothy An-thy Chan其他文献
Timothy An-thy Chan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Timothy An-thy Chan', 18)}}的其他基金
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
基因组和微环境决定因素、时间动态以及基于放射的联合疗法的治疗效果
- 批准号:
10746700 - 财政年份:2023
- 资助金额:
$ 80.69万 - 项目类别:
Project 3 Molecular Mechanisms Underlying Therapy Response to Radiation and Immune Checkpoint Blockade
项目 3 辐射和免疫检查点封锁治疗反应的分子机制
- 批准号:
10818969 - 财政年份:2022
- 资助金额:
$ 80.69万 - 项目类别:
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
基因组和微环境决定因素、时间动态以及基于放射的联合疗法的治疗效果
- 批准号:
10875876 - 财政年份:2022
- 资助金额:
$ 80.69万 - 项目类别:
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
基因组和微环境决定因素、时间动态以及基于放射的联合疗法的治疗效果
- 批准号:
10704661 - 财政年份:2022
- 资助金额:
$ 80.69万 - 项目类别:
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
基因组和微环境决定因素、时间动态以及基于放射的联合疗法的治疗效果
- 批准号:
10526300 - 财政年份:2022
- 资助金额:
$ 80.69万 - 项目类别:
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
项目 1 Sacituzumab 联合放射治疗膀胱癌的遗传和免疫机制
- 批准号:
10704713 - 财政年份:2022
- 资助金额:
$ 80.69万 - 项目类别:
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
项目 1 Sacituzumab 联合放射治疗膀胱癌的遗传和免疫机制
- 批准号:
10526303 - 财政年份:2022
- 资助金额:
$ 80.69万 - 项目类别:
相似国自然基金
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
- 批准号:Y24H280055
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
- 批准号:82330111
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
- 批准号:82373169
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
- 批准号:32300137
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于AT2/ACE2/Ang(1-7)/MAS轴调控心脏-血管-血液系统性重构演变规律研究心衰气虚血瘀证及其益气通脉活血化瘀治法生物学基础
- 批准号:82305216
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
- 批准号:32302080
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
- 批准号:82305171
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
刺参自溶引发机制中ACE2调控靶点的调控网络研究
- 批准号:32372399
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
Spike变异对新冠病毒抗原性及ACE2种属嗜性的影响研究
- 批准号:82272305
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
新型コロナウイルス感染阻害能を有する抗ACE2抗体の阻害機構に関する構造基盤解明
阐明具有抑制新型冠状病毒感染能力的抗ACE2抗体抑制机制的结构基础
- 批准号:
24K09338 - 财政年份:2024
- 资助金额:
$ 80.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ACE2のユビキチン化を介したコロナウイルス感染機構の解明と創薬への挑戦
通过ACE2泛素化阐明冠状病毒感染机制和药物发现的挑战
- 批准号:
22KJ2499 - 财政年份:2023
- 资助金额:
$ 80.69万 - 项目类别:
Grant-in-Aid for JSPS Fellows
ACE2阻害薬およびERK経路阻害薬による慢性腎炎進展抑制効果の検証
ACE2抑制剂和ERK通路抑制剂抑制慢性肾炎进展的效果验证
- 批准号:
23K14982 - 财政年份:2023
- 资助金额:
$ 80.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Large-scale compatibility assessments between ACE2 proteins and diverse sarbecovirus spikes
ACE2 蛋白和多种 sarbecovirus 尖峰之间的大规模兼容性评估
- 批准号:
10722852 - 财政年份:2023
- 资助金额:
$ 80.69万 - 项目类别:
一次線毛とコロナウイルス感染におけるACE2の役割の解明
阐明 ACE2 在原发菌毛和冠状病毒感染中的作用
- 批准号:
22KF0004 - 财政年份:2023
- 资助金额:
$ 80.69万 - 项目类别:
Grant-in-Aid for JSPS Fellows
The regulatory roles of ACE2 and its interaction with Nrf2 in arsenic-induced endothelial dysfunction in experimental and epidemiological studies
实验和流行病学研究中 ACE2 的调节作用及其与 Nrf2 的相互作用在砷诱导的内皮功能障碍中的作用
- 批准号:
23K16310 - 财政年份:2023
- 资助金额:
$ 80.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of ACE2 in the mechanism of intestinal regeneration
ACE2在肠道再生机制中的作用
- 批准号:
23K15078 - 财政年份:2023
- 资助金额:
$ 80.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Research and development of a novel pediatric anti-obesity medicine via ACE2 activation in DIZE
通过 DIZE 中 ACE2 激活研发新型儿科抗肥胖药物
- 批准号:
23K15417 - 财政年份:2023
- 资助金额:
$ 80.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Lung delivery of novel ACE2 variants for COVID-19
针对 COVID-19 的新型 ACE2 变体的肺部输送
- 批准号:
10483042 - 财政年份:2022
- 资助金额:
$ 80.69万 - 项目类别:
ACE2 on gut barrier dysfunction and BRB disruption
ACE2 对肠道屏障功能障碍和 BRB 破坏的影响
- 批准号:
10535485 - 财政年份:2022
- 资助金额:
$ 80.69万 - 项目类别: